Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-07-07T22:23:26.907Z Has data issue: false hasContentIssue false

9 - Therapeutic decision making in hematopoietic stem cell transplantation for multiple myeloma

Published online by Cambridge University Press:  31 July 2009

Reinhold Munker ,
Hillard M. Lazarus  and
Kerry Atkinson
By
Oscar F. Ballester
Reinhold Munker
Affiliation:
Louisiana State University
Hillard M. Lazarus
Affiliation:
University Hospitals Case Medical Center
Kerry Atkinson
Affiliation:
University of Queensland
Get access
Type
Chapter
Information
The BMT Data Book , pp. 139 - 156
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Attal, M, Harousseau, JL, Stoppa, AM, et al. 1996. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335: 91–97.CrossRefGoogle ScholarPubMed
Attal, M, Harousseau, JL, Facon, T, et al. 2003. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349: 2495–502.CrossRefGoogle ScholarPubMed
Attal, M, Harousseau, JL, Leyvraz, S, et al. 2006. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108: 3289–94.CrossRefGoogle ScholarPubMed
Barlogie, B, Kyle, RA, Anderson, KC, et al. 2006. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 24: 929–36.CrossRefGoogle ScholarPubMed
Barlogie, B, Tricot, G, Anaissie, E, et al. 2006. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354: 1021–30.CrossRefGoogle ScholarPubMed
Blade, J, Rosinol, L, Sureda, A, et al. 2005. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106: 3755–59.CrossRefGoogle ScholarPubMed
Bruno, B, Rotta, M, Patriarca, F, et al. 2006. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356: 1110–20.CrossRefGoogle Scholar
Cavo, M, Tossi, P, Zamagni, E, et al. 2007. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25: 2434–41.CrossRefGoogle ScholarPubMed
Child, JA, Morgan, GJ, Davies, FE, et al. 2003. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348: 1875–83.CrossRefGoogle ScholarPubMed
Durie, BGM, Harousseau, JL, Miguel, JS, et al. 2006. International uniform response criteria for multiple myeloma. Leukemia 20: 1467–73.CrossRefGoogle ScholarPubMed
Durie, BGM, Jacobson, J, Barlogie, B, and Crowley, J. 2004. magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in Southwest Oncology Group chemotherapy trials. J Clin Oncol 22: 1857–63.CrossRefGoogle ScholarPubMed
Facon, T, Mary, JY, Hulin, C, et al. 2005. Major superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 106: abstract 780.Google Scholar
Fermand, JP, Katsahian, S, Divine, M, Leblond, V, Dreyfus, F, Macro, M. 2005. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23: 9227–33.CrossRefGoogle Scholar
Fermand, JP, Ravaud, P, Chevret, S, et al. 1998. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92: 3131–36.Google ScholarPubMed
Garban, F, Attal, M, Michallet, M, et al. 2006. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99–03 trial) with tandem autologous stem cell transplantation (IFM99–04 trial) in high-risk de novo multiple myeloma. Blood 107: 3474–80.CrossRefGoogle Scholar
Kristinsson, SY, Landgren, O, Dickman, PW, Derolf, AR, Björkholm, M. 2007. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 25: 1993–99.CrossRefGoogle ScholarPubMed
Moreau, P, Facon, T, Attal, M, Hulin, C, Michallet, M, Maloisel, F. 2002. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99: 731–35.CrossRefGoogle Scholar
Palumbo, A, Bringhan, S, Caravita, T, et al. 2006. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 367: 825–83.CrossRefGoogle Scholar
Palumbo, A, Bringhen, S, Petrucci, MT, et al. 2006. A prospective, randomized, Phase III study of melphalan 200 mg/m2 (MEL200) versus melphalan 100 mg/m2 in newly diagnosed myeloma patients. Blood 108: abstract 55.Google Scholar
Palumbo, A, Bringhen, S, Petrucci, MT, et al. 2004. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104: 3052–57.CrossRefGoogle ScholarPubMed
Palumbo, A, Falco, P, Corradini, P, et al. 2007. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian multiple myeloma network. J Clin Oncol 25: 4459–65.CrossRefGoogle Scholar
Pineda-Roman, M, Tricot, G. 2007. High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol 153: 182–94.CrossRefGoogle ScholarPubMed
Segeren, CM, Sonneveld, P, Holt, B, Vellenga, E, Croockewit, AJ. 2003. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101: 2144–51.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×